Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 1

What do parents want from their child's asthma treatment?

Authors Stefan Walzer

Published 15 March 2007 Volume 2007:3(1) Pages 167—175

Stefan Walzer

Analytica International, Untere Herrenstrasse 25, 79539 Loerrach, Germany

Background: Nearly 5 million children in the United States are affected by asthma, which is more than 5% of the population younger than 18 years. In children four years or younger, the prevalence increased 160% from 1980 to 1994. There are several effective drugs that relieve the symptoms of asthma and others are currently being developed, but even when these medications are prescribed, they may be underutilized because parents fear the possibility of adverse events. Up to now there is no knowledge which are the main drivers of caregiver’s preferences for a safe and effective medication for preschool children in general. The study population was caregivers with children aged 4 years or below. Sample size was 42; results were checked by Monte Carlo simulation.

Material and methods: For a conjoint analysis a status quo treatment and hypothetical treatment options were defined by four attributes: Episode-free days, risk of exacerbation, information available for the long-term impact of the treatment, and out-of-pocket expenses. It was possible to use the status quo as the reference scenario, permitting to couch this ranking in terms of a decision to purchase the product. Relative importances for each product attribute as well as utility estimations for each attribute level were calculated.

Results and discussion: The overall result was that the most important feature for an asthma treatment, in this study, was the attribute of episode-free days. On a scale from 0 to 100 this attribute got the calculated relative importance of 44.2. In contrast to this finding is the relative importance of the attribute EXACERBATION, which only reached 16.2, which is the most unimportant attribute of the attributes offered. Even the variable INFORMATION available on long-term effects in children between 4 years and 14 years of age was more important than the side effects (19.2). Out-of-pocket expenses per month were the second most (relative) important attribute (20.5).

Keywords: utility, conjoint analysis, preference study, health economics, discrete-choice analysis

Download Article [PDF] 

Readers of this article also read:

Validity of a procedure to identify patients with chronic idiopathic thrombocytopenic purpura in the Danish National Registry of Patients

Katrine Edith Klith Heden, Annette Østergaard Jensen, Dora Körmendiné Farkas, Mette Nørgaard

Clinical Epidemiology 2009, 1:7-10

Published Date: 19 February 2009

Adverse effects of fullerenes on endothelial cells: Fullerenol C60(OH)24 induced tissue factor and ICAM-1 membrane expression and apoptosis in vitro

Monique P Gelderman, Olga Simakova, Jeffrey D Clogston, Anil K Patri, Sheena F Siddiqui, et al

International Journal of Nanomedicine 2008, 3:59-68

Published Date: 7 March 2008

The use of amisulpride in the treatment of acute psychosis

Philippe Nuss, Martina Hummer, Cédric Tessier

Therapeutics and Clinical Risk Management 2007, 3:3-11

Published Date: 15 March 2007

Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study

Gian Luigi Marseglia, Mariangela Tosca, Ignazio Cirillo, Amelia Licari, Maddalena Leone, Alessia Marseglia, Anna Maria Castellazzi, Giorgio Ciprandi

Therapeutics and Clinical Risk Management 2007, 3:13-17

Published Date: 15 March 2007

Therapy of autoimmune bullous diseases

Diya F Mutasim

Therapeutics and Clinical Risk Management 2007, 3:29-40

Published Date: 15 March 2007

Comparison of echinocandin antifungals

Gregory Eschenauer, Daryl D DePestel, Peggy L Carver

Therapeutics and Clinical Risk Management 2007, 3:71-97

Published Date: 15 March 2007

Etanercept in the treatment of rheumatoid arthritis

Boulos Haraoui, Vivian Bykerk

Therapeutics and Clinical Risk Management 2007, 3:99-105

Published Date: 15 March 2007

Adalimumab in the treatment of arthritis

Philip J Mease

Therapeutics and Clinical Risk Management 2007, 3:133-148

Published Date: 15 March 2007

Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia

R Lozano, MG Peralta Concha, A Montealegre, L de Leon, J Ortiz Villalba, et al

Therapeutics and Clinical Risk Management 2007, 3:149-155

Published Date: 15 March 2007